Our Aproach
Most cancer patients in Latin America lack access to molecular tests that guide prognosis and treatment decisions. Existing solutions are centralized, expensive, and designed for healthcare systems in Europe or the United States, leaving clinicians without actionable tools to personalize care and patients without equitable access to precision oncology.
Building precision oncology for emerging countries
PreGen applies artificial intelligence to gene expression data to develop clinically actionable prognostic and predictive tests, designed from the ground up for decentralized deployment. Our approach prioritizes biological rigor, clinical validation, and regulatory feasibility, while aligning cost, infrastructure, and workflows with the constraints of the healthcare systems of emerging countries.
Our Solution
Clinically validated tests that inform real treatment decisions
PreGen develops molecular tests that stratify cancer patients by risk and predict response to specific treatments, including immunotherapy. Our first products focus on prostate cancer and is designed to work with standard PCR equipment, widely available after the COVID-19 pandemic.
Each test is validated in regional patient cohorts and designed to integrate seamlessly into clinical decision-making, improving outcomes while avoiding unnecessary treatments.
Patient’s journey
STEP 01
PSA TEST indicates risk of prostate cancer.
STEP 02
CANCER confirmed through Biopsy
STEP 03
PREGEN PCR KITS are performed on the biopsy, in every health center.
STEP 04
RISK SCORE calculated in our web platform, and results presented to the clinician.
STEP 05
TREATMENT The right treatment, at the right time, guided by PreGen.
Our Platform
A scalable AI platform for multitumor precision oncology
Our platform combines gene expression profiling, machine learning models, and a modular development framework that enables rapid expansion across tumor types. This allows PreGen to evolve from individual tests into a multitumor diagnostic platform, supporting multiple indications, partnerships with pharma, and long-term scalability across Latin America.
Tumor Types
Our team
Daniel Alonso
Co-Founder
About Us
PreGen was founded by a multidisciplinary team with deep experience in oncology research, bioinformatics, clinical validation, and biotechnology commercialization. The team combines expertise in gene expression analysis, machine learning, translational oncology, and regulatory strategy, with direct access to clinical cohorts and real-world healthcare settings in Latin America. This combination enables PreGen to translate advanced molecular science into clinically validated, accessible diagnostic solutions with regional impact and global relevance.
Our Partners
Contact Us
We wait for your contact
We’d be glad to connect. If you’re interested in learning more about our technology, exploring partnerships, or discussing collaboration opportunities, we invite you to get in touch.